🧾 What This Document Is

This is Alnylam's DEF 14A, or Definitive Proxy Statement. It's a formal document sent to shareholders ahead of the company's annual meeting. Its purpose is to provide all the information needed for shareholders to vote on important company matters. Think of it as an agenda and a detailed info packet for the big annual shareholder meeting.

🏢 What The Company Does

👉 In simple terms... Alnylam is a pioneering biotech company that turns Nobel Prize-winning science into real medicines. They specialize in RNA interference (RNAi) technology, a powerful method to "silence" genes that cause disease. They have several approved drugs for rare conditions and a deep pipeline of new treatments in development.

🗳️ The Annual Meeting & Your Vote

You are being asked to vote on four key items at the virtual meeting on May 20, 2026:

** elect three directors** (Stuart Arbuckle, Yvonne Greenstreet, and Elliott Sigal) to the board for a 3-year term.
** approve executive compensation** (an advisory, non-binding "say-on-pay" vote).
ratify the selection of PricewaterhouseCoopers LLP as the independent auditing firm for 2026.
Transact any other business that may come up.

👉 Why it matters: Your vote directly influences the company's leadership and oversight. The board recommends voting FOR all three proposals.

👥 Meet the Director Nominees

The board is asking you to elect three Class I directors:

Stuart A. Arbuckle (Age 60): Former COO of Vertex Pharmaceuticals. Brings 30+ years of global commercial and leadership experience from top biopharma companies like Amgen and GlaxoSmithKline.
Yvonne L. Greenstreet, M.D. (Age 63): The current CEO of Alnylam. Provides deep operational knowledge and over 25 years of industry experience in drug development and commercialization.
Elliott Sigal, M.D., Ph.D. (Age 74): Former Chief Scientific Officer of Bristol-Myers Squibb. Chairs the board's Science and Technology Committee, bringing decades of R&D leadership.

👉 Why it matters: These nominees bring a blend of commercial prowess, scientific depth, and direct company leadership—critical skills for executing Alnylam's "Alnylam 2030" growth strategy.

🏛️ Corporate Governance Highlights

Alnylam emphasizes strong governance:

Independent Oversight: 9 of 10 directors are independent. All board committees (Audit, Compensation, Nominating, Science) are 100% independent.
Accountability: They use a majority voting standard for director elections (a director who doesn't get more "For" votes than "Against" must resign).
Aligned Interests: Strong stock ownership rules for executives and directors. They have a clawback policy to recoup incentive pay if needed.
Risk Oversight: The board, through its committees, actively oversees risks—from clinical trials and regulations to cybersecurity.

💰 Executive Compensation ("Say-on-Pay")

You are voting to approve, on an advisory basis, the compensation of Alnylam's named executive officers. The full details are in the "Compensation Discussion and Analysis" section of the proxy, which breaks down salaries, bonuses, and stock awards.

👉 Why it matters: This vote lets shareholders express approval or disapproval of how the company pays its top executives. The board's Compensation Committee believes the pay structure motivates long-term performance without encouraging excessive risk.

📅 Key Dates & Logistics

Record Date: March 25, 2026. Only shareholders on this date can vote.
Annual Meeting: May 20, 2026, at 10:30 a.m. ET.
Location: Virtual only at www.virtualshareholdermeeting.com/ALNY2026. You need your 16-digit control number to attend and vote.
Vote Deadline: 11:59 p.m. ET on May 19, 2026 for votes submitted online, by phone, or by mail in advance.

⚖️ Big Picture: Strengths & Considerations

👍 Strengths:
- Scientific Leadership: Clear pioneer and leader in the validated RNAi field.
- Commercial Execution: Multiple approved and marketed products, with established partnerships (Novartis, Sanofi).
- Strong Governance: High level of board independence and formal policies to protect shareholder interests.
- Strategic Clarity: The "Alnylam 2030" plan provides a clear roadmap for growth and profitability.
⚠️ Considerations/Risks:
- Complex Business: Biotech R&D is inherently risky; clinical trial and regulatory setbacks can occur.
- Market & Competition: Operates in a competitive and heavily regulated pharmaceutical landscape.
- Classified Board: While they defend it as promoting long-term strategy, a staggered board (where only 1/3 of directors are elected each year) can make it harder for shareholders to effect change quickly.

🧠 The Analogy

Think of Alnylam like a specialized research university that has also built its own highly successful tech-transfer commercialization arm. The Board of Directors is like the university's Board of Trustees—they don't run the daily labs (management does), but they hire the President (CEO), set the long-term research strategy (Alnylam 2030), ensure the institution is well-funded and ethically run (governance), and are ultimately accountable to the university's stakeholders (you, the shareholders).

🧩 Final Takeaway

Alnylam is holding its annual shareholder meeting to elect directors, approve pay, and ratify its auditor. The company presents itself as a scientific leader with a mature commercial portfolio and strong governance. Your vote is a chance to endorse the current leadership and strategy as they aim to deliver sustained, profitable growth through 2030.

ALNYLAM PHARMACEUTICALS, INC. — DEF 14A Filing